|
Adrenergic Receptors:
ADRA1A; adrenergic, alpha-1A-, receptor, 8p21-p11.2
ADRA1B; adrenergic, alpha-1B-, receptor, 5q23-q32
ADRA1D; adrenergic, alpha-1D-, receptor, 20p13
ADRA2A; adrenergic, alpha-2A-, receptor, 10q24-q26
ADRA2B; adrenergic, alpha-2B-, receptor, 2p13-q13
ADRA2C; adrenergic, alpha-2C-, receptor, 4p16
ADRB1; adrenergic, beta-1-, receptor, 10q24-q26
ADRB2; adrenergic, beta-2-, receptor, surface, 5q31-q32
ADRB3; adrenergic, beta-3-, receptor, 8p12-p11.2
DRD1; dopamine receptor D1, 5q35.1
DRD1IP; dopamine receptor D1 interacting protein, 10q26.3
DRD2; dopamine receptor D2, 11q23
DRD3; dopamine receptor D3, 3q13.3
DRD4; dopamine receptor D4, 11p15.5
DRD5; dopamine receptor D5, 4p16.1
TARBP1; TAR (HIV) RNA binding protein 1, 1q42.3
TARBP2; TAR (HIV) RNA binding protein 2, 12q12-q13
TARDBP; TAR DNA binding protein, 1p36.22
Ion Channels / Transporters:
ABCB1; ATP-binding cassette, sub-family B (MDR/TAP), member 1, 7q21.1
CACNA1A; calcium channel, voltage-dependent, P/Q type, alpha 1A subunit, 19p13.2-p13.1
CACNA1C; calcium channel, voltage-dependent, L type, alpha 1C subunit, 12p13.3
CACNA1D; calcium channel, voltage-dependent, L type, alpha 1D subunit, 3p14.3
CACNA1G; calcium channel, voltage-dependent, alpha 1G subunit, 17q22
CACNA1S; calcium channel, voltage-dependent, L type, alpha 1S subunit, 1q32
KCNA10; potassium voltage-gated channel, shaker-related subfamily, member 10, 1p13.1
KCNA2; potassium voltage-gated channel, shaker-related subfamily, member 2, 1p13
KCNA3; potassium voltage-gated channel, shaker-related subfamily, member 3, 1p13.3
KCNA4; potassium voltage-gated channel, shaker-related subfamily, member 4, 11p14
KCNA5; potassium voltage-gated channel, shaker-related subfamily, member 5, 12p13
KCNA6; potassium voltage-gated channel, shaker-related subfamily, member 6, 12p13
KCNA7; potassium voltage-gated channel, shaker-related subfamily, member 7, 19q13.3
KCNB1; potassium voltage-gated channel, Shab-related subfamily, member 1, 20q13.2
KCNJ1; potassium inwardly-rectifying channel, subfamily J, member 1, 11q24
KCNJ3; potassium inwardly-rectifying channel, subfamily J, member 3, 2q24.1
KCNJ5; potassium inwardly-rectifying channel, subfamily J, member 5, 11q24
KCNMA1; potassium large conductance calcium-activated channel, subfamily M, alpha member 1, 10q22-q23
KCNMB1; potassium large conductance calcium-activated channel, subfamily M, beta member 1, 5q34
KCNN4; potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4, 19q13.2
NEDD4L; neural precursor cell expressed, developmentally down-regulated 4-like, 18q21
P2RX2; purinergic receptor P2X, ligand-gated ion channel, 2, 12q24.33
P2RX3; purinergic receptor P2X, ligand-gated ion channel, 3, 11q12
P2RXL1; purinergic receptor P2X-like 1, orphan receptor, 22q11.21
SCNN1A; sodium channel, nonvoltage-gated 1 alpha, 12p13
SCNN1B; sodium channel, nonvoltage-gated 1, beta (Liddle syndrome), 16p12.2-p12.1
SCNN1D; sodium channel, nonvoltage-gated 1, delta, 1p36.3-p36.2
SCNN1G; sodium channel, nonvoltage-gated 1, gamma, 16p12
SLC9A3; solute carrier family 9 (sodium/hydrogen exchanger), isoform 3, 5p15.3
SLC9A3R1; solute carrier family 9 (sodium/hydrogen exchanger), isoform 3 regulator 1, 17q25.1
TRPC1; transient receptor potential cation channel, subfamily C, member 1, 3q22-q24
TRPC2; transient receptor potential cation channel, subfamily C, member 2, 11p15.4-p15.3
TRPC3; transient receptor potential cation channel, subfamily C, member 3, 4q27
TRPC4; transient receptor potential cation channel, subfamily C, member 4, 13q13.1-q13.2
TRPC5; transient receptor potential cation channel, subfamily C, member 5, Xq23
TRPC6; transient receptor potential cation channel, subfamily C, member 6, 11q21-q22
TRPC7; transient receptor potential cation channel, subfamily C, member 7, 5q31.1
TRPM2; transient receptor potential cation channel, subfamily M, member 2, 21q22.3
Catecholamine Biosynthesis:
DBH; dopamine beta-hydroxylase (dopamine beta-monooxygenase), 9q34
DDC; dopa decarboxylase (aromatic L-amino acid decarboxylase), 7p11
PEMT; phosphatidylethanolamine N-methyltransferase, 17p11.2
PHOX2A; paired-like (aristaless) homeobox 2a, 11q13.2
PHOX2B; paired-like homeobox 2b, 4p12
PNMT; phenylethanolamine N-methyltransferase, 17q21-q22
TH; tyrosine hydroxylase, 11p15.5
Catecholamine Metabolism / Transport:
CHGA; chromogranin A (parathyroid secretory protein 1), 14q32
CHGB; chromogranin B (secretogranin 1), 20pter-p12
COMT; catechol-O-methyltransferase, 22q11.21-q11.23
GNAS; GNAS complex locus, 20q13.2-q13.3
MAOA; monoamine oxidase A, Xp11.4-p11.3
MAOB; monoamine oxidase B, Xp11.23
SCG2; secretogranin II (chromogranin C), 2q35-q36
SLC11A2; solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2, 12q13
SLC12A1; solute carrier family 12 (sodium/potassium/chloride transporters), member 1, 15q15-q21.1
SLC12A2; solute carrier family 12 (sodium/potassium/chloride transporters), member 2, 5q23.3
SLC12A3; solute carrier family 12 (sodium/chloride transporters), member 3, 16q13
SLC12A4; solute carrier family 12 (potassium/chloride transporters), member 4, 16q22.1
SLC12A5; solute carrier family 12, (potassium-chloride transporter) member 5, 20q13.12
SLC12A6; solute carrier family 12 (potassium/chloride transporters), member 6, 15q13-q15
SLC12A7; solute carrier family 12 (potassium/chloride transporters), member 7, 5p15
SLC12A8; solute carrier family 12 (potassium/chloride transporters), member 8,
SLC12A9; solute carrier family 12 (potassium/chloride transporters), member 9, 7q22
SLC15A4; solute carrier family 15, member 4, 12q24.32
SLC16A12; solute carrier family 16 (monocarboxylic acid transporters), member 12, 10q23.32
SLC17A8; solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 8, 12q23.1
SLC18A1; solute carrier family 18 (vesicular monoamine), member 1, 8p21.3
SLC18A2; solute carrier family 18 (vesicular monoamine), member 2, 10q25
SLC22A10; solute carrier family 22 (organic anion/cation transporter), member 10, 11q
SLC22A11; solute carrier family 22 (organic anion/cation transporter), member 11, 11q13.1
SLC22A13; solute carrier family 22 (organic cation transporter), member 13, 3p21.3
SLC22A14; solute carrier family 22 (organic cation transporter), member 14, 3p21.3
SLC22A15; solute carrier family 22 (organic cation transporter), member 15, 1p13.1
SLC22A16; solute carrier family 22 (organic cation transporter), member 16, 6q22.1
SLC22A17; solute carrier family 22 (organic cation transporter), member 17, 14q11.2
SLC22A18; solute carrier family 22 (organic cation transporter), member 18, 11p15.5
SLC22A3; solute carrier family 22 (extraneuronal monoamine transporter), member 3, 6q26-q27
SLC22A4; solute carrier family 22 (organic cation transporter), member 4, 5q23.3
SLC22A5; solute carrier family 22 (organic cation transporter), member 5, 5q31
SLC22A9; solute carrier family 22 (organic anion/cation transporter), member 9, 11q13.1
SLC25A1; solute carrier family 25 (mitochondrial carrier; citrate transporter), member 1, 22q11.21
SLC25A2; solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 2, 5q31
SLC25A3; solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3, 12q23
SLC25A4; solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4, 4q35
SLC25A5; solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5, Xq24-q26
SLC25A6; solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 6,
SLC6A2; solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2, 16q12.2
Nicotinic Cholinergic Responses:
ACHE; acetylcholinesterase (YT blood group), 7q22
BCHE; butyrylcholinesterase, 3q26.1-q26.2
CHAT; choline acetyltransferase, 10q11.2
CHRM1; cholinergic receptor, muscarinic 1, 11q13
CHRM2; cholinergic receptor, muscarinic 2, 7q31-q35
CHRM3; cholinergic receptor, muscarinic 3, 1q41-q44
CHRNA3; cholinergic receptor, nicotinic, alpha polypeptide 3, 15q24
CHRNA5; cholinergic receptor, nicotinic, alpha polypeptide 5, 15q24
CHRNA7; cholinergic receptor, nicotinic, alpha polypeptide 7, 15q14
CHRNB2; cholinergic receptor, nicotinic, beta polypeptide 2 (neuronal), 1q21.3
CHRNB4; cholinergic receptor, nicotinic, beta polypeptide 4, 15q24
SLC18A3; solute carrier family 18 (vesicular acetylcholine), member 3, 10q11.2
Nitric Oxide Synthases:
NOS1; nitric oxide synthase 1 (neuronal), 12q24.2-q24.31
NOS2A; nitric oxide synthase 2A (inducible, hepatocytes), 17q11.2-q12
NOS3; nitric oxide synthase 3 (endothelial cell), 7q36
Peptides / Receptors:
CRH; corticotropin releasing hormone, 8q13
CRP; C-reactive protein, pentraxin-related, 1q21-q23
CXCR4; chemokine (C-X-C motif) receptor 4, 2q21
GHR; growth hormone receptor, 5p13-p12
KLK1; kallikrein 1, renal/pancreas/salivary, 19q13.3
NPY; neuropeptide Y, 7p15.1
NPY1R; neuropeptide Y receptor Y1, 4q31.3-q32
NPY2R; neuropeptide Y receptor Y2, 4q31
NPY5R; neuropeptide Y receptor Y5, 4q31-q32
PPYR1; pancreatic polypeptide receptor 1, 10q11.2
PYY; peptide YY, 17q21.1
Prostacyclin:
PTGIR; prostaglandin I2 (prostacyclin) receptor (IP), 19q13.3
PTGIS; prostaglandin I2 (prostacyclin) synthase, 20q13.11-q13.13
Renin / Angiotensin:
ACE; angiotensin I converting enzyme (peptidyl-dipeptidase A) 1, 17q23
AGT; angiotensinogen (serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 8), 1q42-q43
AGTR1; angiotensin II receptor, type 1, 3q21-q25
AGTR2; angiotensin II receptor, type 2, Xq22-q23
ANGPT1; angiopoietin 1, 8q22.3-q23
APOE; apolipoprotein E, 19q13.2
LPL; lipoprotein lipase, 8p22
REN; renin, 1q32
Serotonergic Responses:
HTR1A; 5-hydroxytryptamine (serotonin) receptor 1A, 5q11.2-q13
HTR2C; 5-hydroxytryptamine (serotonin) receptor 2C, Xq24
SLC6A4; solute carrier family 6 (neurotransmitter transporter, serotonin), member 4, 17q11.1-q12
TPH1; tryptophan hydroxylase 1 (tryptophan 5-monooxygenase), 11p15.3-p14
TPH2; tryptophan hydroxylase 2, 12q21.1
Signal Transduction:
ADCY1; adenylate cyclase 1 (brain), 7p13-p12
ADCY2; adenylate cyclase 2 (brain), 5p15.3
ADCY3; adenylate cyclase 3, 2p24-p22
ADCY4; adenylate cyclase 4, 14q11.2
ADCY4; adenylate cyclase 4, 14q11.2
ADCY5; adenylate cyclase 5, 3q13.2-q21
ADCY6; adenylate cyclase 6, 12q12-q13
ADCY7; adenylate cyclase 7, 16q12-q13
ADCY8; adenylate cyclase 8 (brain), 8q24
ADCY9; adenylate cyclase 9, 16p13.3
ADMR; adrenomedullin receptor, 12q13.3
ADRBK1; adrenergic, beta, receptor kinase 1, 11q13
ADRBK2; adrenergic, beta, receptor kinase 2, 22q11
AKAP1; A kinase (PRKA) anchor protein 1, 17q21-q23
ARRB2; arrestin, beta 2, 17p13
BDKRB2; bradykinin receptor B2, 14q32.1-q32.2
BMPR1A; bone morphogenetic protein receptor, type IA, 10q22.3
BMPR2; bone morphogenetic protein receptor, type II (serine/threonine kinase), 2q33-q34
GNAI1; guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1, 7q21
GNAI2; guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2, 3p21
GNAI3; guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3, 1p13
GNAQ; guanine nucleotide binding protein (G protein), q polypeptide, 9q21
GNAS; GNAS complex locus, 20q13.2-q13.3
GNB3; guanine nucleotide binding protein (G protein), beta polypeptide 3, 12p13
GNB4; guanine nucleotide binding protein (G protein), beta polypeptide 4, 3q26.32
GNB5; guanine nucleotide binding protein (G protein), beta 5, 15q21.2
GRK4; G protein-coupled receptor kinase 4, 4p16.3
GUCY1A2; guanylate cyclase 1, soluble, alpha 2, 11q21-q22
GUCY1B2; guanylate cyclase 1, soluble, beta 2, 13q14.2-q14.3
GUCY2D; guanylate cyclase 2D, membrane (retina-specific), 17p13.1
ITGAL; integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide), 16p11.2
ITPK1; inositol 1,3,4-triphosphate 5/6 kinase, 14q31
NET1; neuroepithelial cell transforming gene 1, 10p15
PLCB1; phospholipase C, beta 1 (phosphoinositide-specific), 20p12
PLCB2; phospholipase C, beta 2, 15q15
PPH1; primary pulmonary hypertension 1, 2q33
RAC1; ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1), 7p22
RAC1P4; ras-related C3 botulinum toxin substrate 1 pseudogene 4, Xq26.3
RAC2; ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2), 22q13.1
RGS1; regulator of G-protein signalling 1, 1q31
RGS2; regulator of G-protein signalling 2, 24kDa, 1q31
RGS3; regulator of G-protein signalling 3, 9q32
RGS4; regulator of G-protein signalling 4, 1q23.3
RGS5; regulator of G-protein signalling 5, 1q23.1
RGS6; regulator of G-protein signalling 6, 14q24.3
RHO; rhodopsin (opsin 2, rod pigment) (retinitis pigmentosa 4, autosomal dominant), 3q21-q24
RHOA; ras homolog gene family, member A, 3p21.3
RHOB; ras homolog gene family, member B, 2p24
RHOC; ras homolog gene family, member C, 1p13.1
RHOD; ras homolog gene family, member D, 11q14.3
RHOG; ras homolog gene family, member G (rho G), 11p15.5-p15.4
RHOH; ras homolog gene family, member H, 4p13
RHOJ; ras homolog gene family, member J, 14q23.2
RHOT1; ras homolog gene family, member T1, 17q11.2
RHOT2; ras homolog gene family, member T2, 16p13.3
RHOU; ras homolog gene family, member U, 1q42.11-q42.3
ROCK1; Rho-associated, coiled-coil containing protein kinase 1, 18q11.1
ROCK2; Rho-associated, coiled-coil containing protein kinase 2, 2p24
SGK; serum/glucocorticoid regulated kinase, 6q23
SLC22A1; solute carrier family 22 (organic cation transporter), member 1, 6q26
SLC22A2; solute carrier family 22 (organic cation transporter), member 2, 6q26
SLC6A3; solute carrier family 6 (neurotransmitter transporter, dopamine), member 3, 5p15.3
SNX1; sorting nexin 1, 15q22.31
SNX10; sorting nexin 10, 7p15.2
SNX11; sorting nexin 11, 17q21.32
SNX12; sorting nexin 12, Xq13.1
SNX13; sorting nexin 13, 7p21.1
SNX14; sorting nexin 14, 6q14.3
SNX15; sorting nexin 15, 11q12
SNX16; sorting nexin 16, 8q21.13
SNX17; sorting nexin 17, 2p23-p22
SNX19; sorting nexin 19, 11q25
SNX2; sorting nexin 2, 5q23
SNX22; sorting nexin 22, 15q22.31
SNX25; sorting nexin 25, 4q35.1
SNX26; sorting nexin 26, 19q13.12
SNX27; sorting nexin family member 27, 1q21.3
SNX3; sorting nexin 3, 6q21
SNX4; sorting nexin 4, 3q21.2
SNX5; sorting nexin 5, 20p11
SNX6; sorting nexin 6, 14q13.1
SNX7; sorting nexin 7, 1p21.3
SNX8; sorting nexin 8, 7p22.3
SNX9; sorting nexin 9, 6q25.1-q26
Oxygenases:
CYP11A1; cytochrome P450, family 11, subfamily A, polypeptide 1, 15q23-q24
CYP11B2; cytochrome P450, family 11, subfamily B, polypeptide 2, 8q21-q22
CYP2D6; cytochrome P450, family 2, subfamily D, polypeptide 6, 22q13.1
CYP3A4; cytochrome P450, family 3, subfamily A, polypeptide 4, 7q21.1
CYP3A5; cytochrome P450, family 3, subfamily A, polypeptide 5, 7q21.1
FMO1; flavin containing monooxygenase 1, 1q23-q25
FMO2; flavin containing monooxygenase 2, 1q23-q25
FMO3; flavin containing monooxygenase 3, 1q23-q25
FMO4; flavin containing monooxygenase 4, 1q23-q25
FMO5; flavin containing monooxygenase 5, 1q21.1
Proteases:
CTSL; cathepsin L, 9q21-q22
Nuclear Hormone Receptors:
NR1H2; nuclear receptor subfamily 1, group H, member 2, 19q13.3-19q13.3
NR1H3; nuclear receptor subfamily 1, group H, member 3, 11p11.2
NR3C2; nuclear receptor subfamily 3, group C, member 2, 4q31.1
PPARA; peroxisome proliferative activated receptor, alpha, 22q12-q13.1
PPARD; peroxisome proliferative activated receptor, delta, 6p21.2-p21.1
PPARG; peroxisome proliferative activated receptor, gamma, 3p25
RARA; retinoic acid receptor, alpha, 17q21
RARB; retinoic acid receptor, beta, 3p24
RARG; retinoic acid receptor, gamma, 12q13
RXRA; retinoid X receptor, alpha, 9q34.3
Others:
ABT1; activator of basal transcription 1, 6p22.1
ACTN4; actinin, alpha 4, 19q13
ADD1; adducin 1 (alpha), 4p16.3
ADD2; adducin 2 (beta), 2p14-p13
CAPN10; calpain 10, 2q37.3
CBS; cystathionine-beta-synthase, 21q22.3
CD2AP; CD2-associated protein, 6p12
CYB561; cytochrome b-561, 17q11-qter
CYBA; cytochrome b-245, alpha polypeptide, 16q24
CYBB; cytochrome b-245, beta polypeptide (chronic granulomatous disease), Xp21.1
GAPD; glyceraldehyde-3-phosphate dehydrogenase, 12p13
GCH1; GTP cyclohydrolase 1 (dopa-responsive dystonia), 14q22.1-q22.2
GSTT1; glutathione S-transferase theta 1, 22q11.23
GSTT2; glutathione S-transferase theta 2, 22q11.2
HSD11B1; hydroxysteroid (11-beta) dehydrogenase 1, 1q32-q41
HSD11B2; hydroxysteroid (11-beta) dehydrogenase 2, 16q22
LGALS9; lectin, galactoside-binding, soluble, 9 (galectin 9), 17q11.2
MTHFR; 5,10-methylenetetrahydrofolate reductase (NADPH), 1p36.3
MTR; 5-methyltetrahydrofolate-homocysteine methyltransferase, 1q43
NPHS1; nephrosis 1, congenital, Finnish type (nephrin), 19q13.1
NPHS2; nephrosis 2, idiopathic, steroid-resistant (podocin), 1q25-q31
SLC22A12; solute carrier family 22 (organic anion/cation transporter), member 12, 11q13.1
SLC22A6; solute carrier family 22 (organic anion transporter), member 6, 11q13.1-q13.2
SLC22A7; solute carrier family 22 (organic anion transporter), member 7, 6p21.2-p21.1
SLC22A8; solute carrier family 22 (organic anion transporter), member 8, 11q11
WT1; Wilms tumor 1, 11p13
XDH; xanthine dehydrogenase, 2p23-p22
|
UCSD NHLBI Program
Sympathetic Neuroeffector Junctions
and Blood Pressure
Human Essential Hypertension
Hypertension
Candidate Loci
Hypertension: |
Home |
Program |
HumChroms |
MouseChroms |
SNPs |
Usage |
Data |
Other: | Longevity Candidate Loci |
DNASYSTEM Home Page |
|
|
Select a locus from the List to the left |
or Search for a locus by yourself. |
|
| The default List to the left shows Human loci, |
| organized by Category. |
|
| Click on the 'Mouse' button to the left |
| to see Mouse loci organized by Category. |
|
| Click on the 'Rat' button to the left |
| to see Rat loci organized by Category. |
|
| Click on the 'Search' button to the left |
| to see ALL loci organized alphabetically, |
| with organism presented as 'Hs' for Human, 'Mm' for Mouse, and 'Rn' for Rat. |
|
Latest update: 27 February, 2005
If you have comments or queries, send email to
Doug Smith
|
|